Phaseline

Targets › ACK1

ACK1 (Activated CDC42 kinase 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2027.

Non-receptor tyrosine-protein and serine/threonine-protein kinase that is implicated in cell spreading and migration, cell survival, cell growth and proliferation. Transduces extracellular signals to cytosolic and nuclear effectors. (UniProt, Q07912)

Open in Phaseline: the race on ACK1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TechnoGenesys(R)-9bMS
ACK1 inhibitor
ACK1Phase 1Metastatic Castration-resistant Prostate Cancer (CRPC)Dec 2027

Conditions

Metastatic Castration-resistant Prostate Cancer (CRPC) (1)

Modalities

small molecule (1)

Companies

TechnoGenesys (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.